Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | PROKR1 | Q8TCW9 | 10/20 | 0.45 |
| ▸ | FPR2 | P25090 | 9/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ACLY | P53396 | 2/20 | 0.39 |
| ▸ | NMT1 | P30419 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388129 | 0.82 | L3MBTL1 (0.43) | MCL1PROKR1FPR2L3MBTL1ACLY | |
| SCHEMBL1641772 | 0.82 | L3MBTL1 (0.43) | MCL1PROKR1FPR2L3MBTL1ACLY | |
| SCHEMBL3941116 | 0.80 | L3MBTL1 (0.42) | MCL1PROKR1FPR2L3MBTL1ACLY | |
| SCHEMBL6205744 | 0.80 | L3MBTL1 (0.42) | MCL1PROKR1FPR2L3MBTL1ACLY | |
| SCHEMBL2650212 | 0.80 | L3MBTL1 (0.46) | MCL1PROKR1FPR2L3MBTL1ACLY | |
| SCHEMBL1626536 | 0.80 | L3MBTL1 (0.42) | MCL1PROKR1FPR2L3MBTL1ACLY | |
| SCHEMBL4895697 | 0.79 | TSHR (0.44) | PROKR1FPR2NMT1GAA | |
| SCHEMBL13677614 | 0.78 | HTR6 (0.44) | MCL1PROKR1FPR2L3MBTL1ACLY | |
| Hydrochloric Acid SCHEMBL27293487 | 0.78 | L3MBTL1 (0.45) | MCL1PROKR1FPR2L3MBTL1ACLY | |
| SCHEMBL9202305 | 0.78 | NMT1 (0.42) | MCL1PROKR1FPR2L3MBTL1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101208299-A | Diarylsulfone sulfonamides and use therof | WYETH CORP (US) | 2008-06-25 | — | — | CN | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | MCL1 1442/4885PROKR1 666/4885FPR2 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.